Traws Pharma Provides Regulatory Update on Influenza Program
Rhea-AI Summary
Traws Pharma (NASDAQ:TRAW) reported a regulatory setback for its influenza program. A planned Phase 2a human influenza challenge study of tivoxavir marboxil (TXM) was deferred following a negative review by the UK MHRA.
The company highlights TXM's animal-model efficacy, maintains focus on long-acting influenza antivirals, is advancing non-mutagenic backup candidates, and reports a cash runway extending to Q1 2027.
Positive
- TXM showed potent efficacy in three animal models of highly pathogenic avian influenza
- TXM has a long-duration pharmacokinetic and antiviral profile suitable for treatment and prevention
- TXM is viewed as retaining potential for emergency use in bird flu outbreaks and high-risk groups
- Company is advancing backup influenza antivirals with TXM-like profile but without mutagenic potential
- Management reiterates influenza antivirals program remains a high priority focus
- Cash runway reported to extend into Q1 2027, supporting continued development
Negative
- UK MHRA issued a negative review of the tivoxavir marboxil influenza program
- Planned Phase 2a human influenza challenge study of TXM has been deferred
- Development of the lead influenza compound has experienced a stated setback
- Regulatory feedback has impacted the timing of the planned challenge study
News Market Reaction – TRAW
On the day this news was published, TRAW declined 40.95%, reflecting a significant negative market reaction. Argus tracked a trough of -28.2% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $19.39M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Hantavirus/Ebola program | Positive | -3.2% | Announced broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks. |
| May 15 | Q1 results, financing | Positive | +15.3% | Reported Q1 2026 results and up to $60M private financing to fund trials. |
| May 8 | Hantavirus candidates plan | Positive | +28.2% | Outlined plans to advance clinical candidates for hantavirus infections. |
| Apr 15 | FY 2025 results, PIPE | Positive | -1.6% | Reported 2025 financials, TXM and ratutrelvir progress, and up to $60M PIPE. |
| Apr 15 | PIPE financing terms | Negative | -22.6% | Announced up to $60M private placement financing at specified share price. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News reactions have been mixed: pipeline updates have often been rewarded, while financings and some broader business updates have seen selling or muted responses.
Over the last few months, Traws highlighted multiple antiviral initiatives, including hantavirus and Ebola programs (May 8 and May 27, 2026) and continued development of tivoxavir marboxil (TXM) for influenza. Earnings updates on April 15 and May 15, 2026 emphasized TXM, ratutrelvir, and an up to $60M PIPE intended to fund operations into Q1 2027. A separate private placement announcement on April 15, 2026 led to a larger selloff. Today’s MHRA-driven deferral directly impacts the previously funded UK influenza challenge plan.
Key Terms
phase 2a medical
pharmacokinetic medical
mutagenic medical
prophylaxis medical
mhra regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).
“Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile consistent with its use for bird flu treatment and prevention,” said C. David Pauza, PhD Chief Science Officer for Traws Pharma, “The product candidate retains potential for emergency use in a bird flu outbreak and for prevention in high-risk populations.” The Company has a portfolio of back-up influenza antiviral compounds and is actively advancing candidates with TXM's long-duration pharmacokinetic and antiviral profile and devoid of any mutagenic potential.
“Influenza, including bird flu, continues to be a major public health threat in the US and worldwide,” commented Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Head of the U.S. Centers for Disease Control and Prevention. “While we have had a setback in the development of our lead compound for influenza, the program continues to be a high priority. Influenza treatment and prevention is especially important for vulnerable populations including elderly and immunocompromised individuals who are at much greater risk for severe influenza compared to the general population.
“We remain committed to advancing long-acting influenza antivirals and continue to believe this modality has meaningful potential in seasonal influenza prophylaxis. While the recent regulatory feedback affects the timing of our planned challenge study, it does not change our conviction in the underlying scientific rationale. With our cash runway extending to Q1 2027, we are advancing alternative candidates designed to preserve TXM’s pharmacokinetics and efficacy, and exclude potential regulatory concerns,” said Iain Dukes, MA, DPhil, Chief Executive Officer for Traws Pharma.
About Traws Pharma, Inc.
Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health including seasonal influenza and H5N1 bird flu, negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, Lassa Fever and COVID-19/Long COVID.
For more information, please visit www.trawspharma.com and follow us on LinkedIn.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, market size, benefits, effectiveness, safety, and the clinical and regulatory plans for tivoxavir marboxil and ratutrelvir and other investigational antiviral agents, as well as plans for its legacy programs. The Company has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the outcome of Traws’ IND filing with the FDA for tivoxavir marboxil, including the current FDA clinical hold; the success and timing of Traws’ clinical trials; Traws’ ability to identify and advance potential clinical candidates for the treatment of Hantavirus infections, Ebola Virus Disease, Lassa Fever, the potential efficacy of ratutrelvir for the treatment of COVID-19, including the potential to reduce the risk of COVID rebound and Long COVID; the potential for tivoxavir marboxil and ratutrelvir and other investigational antiviral agents to gain market acceptance, if and when regulatory approval is obtained, or to become the new standard of care; Traws’ interactions with the FDA, BARDA, CDC, NAFDAC, AMA and similar foreign regulators; collaborations; market conditions; regulatory requirements and pathways for approval; the ongoing need for improved therapy to reduce the frequency of clinical rebound and the concomitant risk for Long COVID; the extent of the spread and threat of pandemic flu including H5N1 bird flu; the Company’s cash projections; Traws’ ability to raise additional capital when needed; and those discussed under the heading “Risk Factors” in Traws’ filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.
Traws Pharma Contact:
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
www.trawspharma.com
Investor Contact:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
